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Randomized controlled trials (RCTs) are universally considered as the gold standard for evaluating 
the efficacy of treatments. Their main strength is that, through randomization, they avoid any major 
imbalance between compared groups: therefore, observed outcome differences between groups at 
the end of the trial are most likely related to treatment effects. Since they are inherently prospective 
by design, they also permit stability throughout the study to ensure that all conditions remain 
optimal to test the hypothesis of interest. These include high-quality follow-up, reinforced 
adherence, etc. Consequently, these studies can reach the highest level of internal validity, provided 
that all quality standards are followed, such as those defined by CONSORT guidelines [1].
However, this should not lead to a generalization of the applicability of findings, i.e. to credit these 
studies with a high level of external validity: by design, a RCT recruits a specific, well-defined 
population. Since human beings are biologically heterogeneous, they do not react uniformly to 
stimuli such as pharmacological agents. Thus, the results observed in a given population should be 
applied only in this population and not extrapolated to others without complementary testing [2].
A major difficulty here is that, in essence, subjects participating in a randomized trial may be 
significantly different from those who decline to participate or would not be invited based on the 
investigator’s decision (selection bias). For this reason, a pragmatic statement could be that the 
populations and/or context/setting of a RCT may often not be fully representative of what could 
happen in real life.
This  limitation makes other (complementary) designs important, with the potential to determine 
whether results observed in RCTs can be applied to wider populations, or whether other hypotheses 
should be considered and tested [3]. This is where real-life (or real-world) research (RLR) can 
contribute significantly by observing treatment effects in unselected patients. Thereby, RLR has the 
potential to (1) examine the possibility of extrapolating the results of RCTs to different patient 
populations, confirming or refuting effectiveness, and (2) examine the effects of the intervention in 
unselected populations. But the presence of bias could lead to misleading conclusions; for 
comparative effectiveness designs, the most frequent type of bias is the presence of more or less 
apparent differences between groups, which can be difficult to detect [4].
To benefit fully from what RLR can provide, high quality protocols need to be developed and the 
interpretation of results needs to be cautious. As for RCTs, quality standards have been proposed and 
work is ongoing in this field to address and refine crucial methodological issues.





























































RLR is relevant for a wide range of stakeholders involved in the use, conduct, review and/or quality 
appraisal of therapeutic research: patients, clinicians, researchers, reviewers, policy makers, 
institutions, guideline developers, etc [5].
The Respiratory Effectiveness Group (REG) was created in 2013 to promote high-quality real-life 
respiratory research. REG is involved in establishing and communicating quality standards for RLR, 
promoting RLR projects, providing leadership and examples of excellence in RLR, offering ethical 
review for RLR projects, engaging all stakeholders interested in RLR and facilitating collaborative 
networking in this field.
 
We define
Real-Life Research is research that includes the widest possible range of the target patients 
population, cared for in naturalistic conditions, with an intensity of follow-up that does not exceed 
what is provided in routine care [2]. 
Within the research framework proposed by the REG (Figure 1), RLR corresponds to the top right of 
the graph (patients diagnosed as (condition), open design, naturalistic setting) with the “real-life” 
character decreasing towards the bottom left corner (highly selected patients, randomized blinded 
design, highly controlled setting).
Tools other than the REG framework have been proposed to determine the extent to which a study is 
on the highly controlled vs fully naturalistic side of research, i.e., where it sits within the efficacy-to-
effectiveness continuum [6].
We know
When performed appropriately [1], traditional RCTs are a source of highly reliable evidence on 
treatment effects, with high internal validity.
However, especially when performed for registration purposes, they rely on populations selected to 
maximize the chance of demonstrating efficacy. Investigators tend to avoid recruiting patients with 
too many comorbidities or concomitant treatments, both to comply with inclusion and exclusion 
criteria, control variables and to limit the risk of adverse effects that represent a significant burden 
for patients and clinical and research resources. As a result, possible modifiers of treatment effects 
cannot be studied, which limits the generalizability of findings (limited external validity). For instance, 
many asthma RCTs do not include current smokers or obese patients, as both of these conditions are 





























































known to modify treatment effects [7, 8]. In such RCTs, patients receive detailed instructions and are 
closely followed to ensure proper inhaler use and adherence. They benefit from easier and quicker 
access to care, and often form stronger relationships with healthcare providers.
Altogether, several studies found that populations recruited in asthma or COPD treatment trials are 
representative of only a very small minority of these patient populations, not exceeding 15% in many 
studies [9–17].
RLR may be observational (prospective or retrospective, e.g. using medico-administrative databases) 
or interventional (pragmatic trials). Importantly, for each of these options strict quality criteria have 
been developed to allow readers to determine the strength of the produced evidence. These include 
the CONSORT statement extension for pragmatic trials [18], STROBE statement for observational 
studies in epidemiology [19], EMA-ENCePP checklist for pharmacoepidemiology and 
pharmacovigilance studies [20], UNLOCK initiative on quality criteria and minimal datasets 
requirements for observational studies [21], PRISMA for meta-analyses [22] and StaRI standards for 
implementation trials [23]. Recently, the REG has developed, tested and released the REal Life 
EVidence AssessmeNt Tool (RELEVANT) to assess the quality of real-life comparative effectiveness 
research [24, 25]. This tool relies on previously established quality standards proposed by REG and 
others [4, 26, 27] and is expected to facilitate both study design and appraisal . 
Accordingly, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
system acknowledges the possibility of upgrading the level of evidence provided by an observational 
study when all relevant quality criteria are satisfied, and the evidence is deemed “overwhelming”. 
Conversely, failure to meet these criteria will result in a downgrading of the evidence provided [28].
RLR cannot replace traditional RCTs but can be useful and even crucial to complement them: RLR 
studies of sufficient quality (high external validity) can help verifying and extending the applicability 
of RCTs’ findings [29]. Although definitive conclusions cannot usually be drawn from results of 
observational studies (due to the possibility of residual confounding), they can be confirmatory 
and/or hypothesis-generating regarding, e.g., treatment effectiveness in subgroups of interest, safety 
in a wide range of populations, cost-effectiveness in various healthcare systems. When possible, 
pragmatic trials could offer a stronger study design.
As such, RLR needs to be performed and accounted for by all stakeholders involved in issues relating 
to therapy, including patients, clinicians, researchers, reviewers, policy makers, institutions, guideline 
developers. Indeed this requirement is acknowledged in some guidelines document such as the one 
produced by GOLD on COPD management, which underlines that the lack of external validity may 





























































compromise the applicability of trials’ results to a broader population [30]; similarly, the European 
Respiratory Society recently underlined the need to use evidence beyond RCTs when elaborating 
guidelines [31].
We advocate
 For the appraisal and inclusion of high-quality real-life studies in the development of 
clinical practice guidelines
o While theoretically any study can be used to inform guidelines, real-life studies 
are frequently excluded; this may lead to very low number of studies/subjects 
used and consequent agnostic positions that do not help in clinical practice; 
potentially compromising the applicability of guideline recommendations into 
practice.
o RLR may improve the relevance of the guideline to the clinician
o RLR may contribute significantly to the identification of the best treatment 
options by identifying responsive populations, adding value and knowledge to the 
evidence provided by RCTs
 For the use of implementation real life studies of interventions in different countries and 
settings to assess their impact in different populations, environments and health care 
systems. 
 For the use of real-life studies to complement RCTs for registration of new treatment 
modalities
o Regulators are only now starting to understand that different types of real-life 
studies complement evidence for treatment modalities, in particular with regards 
to how their use can be optimised in practice. These real-life studies should be 
used to support decisions relating to the registration of new treatment 
modalities. The application of real-life studies in this context needs to be better 
established and utilised. 
 For the establishment of formal investigation plans/programs of research/development 
and approval processes/post-marketing surveillance to include real-life studies 





























































o In the life cycle of a product, real-life studies offer added value and can be 
helpful, particularly in post-authorisation phases. Long-term investigational plans 
including real-life studies produce added value for all stakeholders.
 For increased education and awareness of the scope, role and requirements of high-
quality real-life studies in respiratory research
o There is some confusion around RLR and the term is used in variable ways. The 
limits and opportunities of different methodologies should be part of the 
education of both researchers, research administrators and practitioners 
 For continuing methodological research to expand and improve the quality and 
interpretability of real-life studies towards clinical practice
o The limits of real-life approaches have not yet been reached and innovation is 
welcome in incorporating new types of evidence into our knowledge base
 For the establishment of well-designed global registries around common respiratory 
conditions to prospectively collect key disease information 
o Registries currently offer a cost-effective approach to longitudinal epidemiology 
with the potential for a much greater role in the future.
 For the accelerated incorporation of RLR into technological advances in the form of 
digital outcomes, eHealth and mHealth in the research/registration/guideline process, in 
parallel to advances in analytical tools to evaluate big data. 
o The rate of technological advancement appears more rapid than our ability to 
evaluate and regulate their impact; the opportunity however of gaining (and 
using) knowledge through novel technological modalities has boundless 
possibilities, which need to be explored within a high-quality and structured 
framework of RLR. 
We conclude
 RLR is now clearly positioned within the therapeutic research framework established by, 
e.g., the REG.
 RLR (high external validity) is necessary to complement results of traditional RCTs (high 
internal validity) regarding treatment effects.





























































 RLR may be confirmatory, extend findings of RCTs in wider populations and settings, and 
generate hypotheses on specific subgroups or situations of interest.
 RLR may also provide evidence where RCTs cannot be performed for reasons relating to 
feasibility, ethics and affordability.
 As such, RLR should always be considered a potentially important contributor to fill 
knowledge gaps.
 High-quality RLR can and should be incorporated by patients, healthcare professionals, 
guidelines developers and policy-makers to guide decision processes.
 Tools to rigorously assess the quality of RLR such as those developed by the REG are now 
available and should be used systematically.
 Finally, researchers should always identify the most appropriate study design to answer a 
well-defined research question, be it classical RCTs, pragmatic RCTs, observational 
studies or implementation research designs.
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Figure 1: the effectiveness research framework. Reproduced from [2] with permission.
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